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B A R E  M E T A L  S T E N T S  V E R S U S  D R U G  E L U T I N G  S T E N T S
Percutaneous coronary intervention (PCI) with stent placement has been proven 
a very effective way to treat patients with significant coronary artery disease (CAD) 
with acute and chronic clinical coronary syndromes. Over the last 8 years drug-elut-
ing stent (DES) use has surpassed bare metal stent (BMS) use, mainly because DES 
reduce significantly the in-stent restenosis and decrease future major adverse cardiac 
events. The use of DES has expanded the application of PCI to more complex CAD 
patients.
The only major, infrequent but critically important, problem with at least the first 
generation DES use is the late stent thrombosis and the required long term dual anti-
platelet treatment, which is probably due to endothelial dysfunction. In real life, although 
a great deal of discussion on on-label and off-label indications has taken place, DES 
are used for all indications except perhaps for simple-short lesions in vessels >3 mm 
in diameter, where BMS use is still acceptable. However, before the decision for DES 
or BMS is made, two things should be considered carefully. Both problems have to 
do with safety, since the effectiveness issue has been resolved.
First, the risk of bleeding inherent to the patient to be treated remains a major is-
sue. This should be classified as low, medium or high. The criteria for high bleeding 
risk are shown in Table 1.
Second, the risk of thromboembolic complications, including stent thrombosis, 
and associated anticoagulant treatment, should be considered when choosing the 
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TABLE 1. Some diagnostic and surgical procedures with a high bleeding risk
Extracorporeal surgery
Intracranial and spinal cord surgery
Abdominal aneurysm resection 
Major peripheral vascular surgery
Extensive cancer surgery (neural, urogenital, cervical, abdominal, breast)
Major orthopaedic surgery (hip and knee replacement, laminectomy)
Extensive reconstructive plastic surgery 
Transurethral resection and bladder interventions
Solid organ biopsy
Intestinal polipectomy 
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appropriate type of stent. Estimated risk <3% is considered 
low. The clinical scenarios for high thromboembolic risk 
requiring oral anticoagulation therapy, which in case of DES 
placement dictates triple therapy (ASA, clopidogrel and oral 
anticoagulation agent), is shown in Table 2. Stent thrombosis 
does not require triple therapy but it should be considered 
carefully in low responders to ASA and clopidogrel.
U N A N S W E R E D  Q U E S T I O N S
There are some remaining questions that will hopefully 
be answered in future studies:
Which patients should undergo dual antiplatelet therapy 
beyond the usual 6-12 month period because of a perma-
nent stent thrombosis risk?
Which scores better predict further benefits in real-life 
from DES? Do scores obtained from clinical studies 
represent real-life patients?
Future techniques analyzing the effect of antiplatelet 
-
-
agents, safer DES, better antiplatelet regimens and better 
medical knowledge will help reduce thrombotic and 
bleeding complications resulting from coronary artery 
revascularization.
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TABLE 2. Some clinical scenarios with a high thromboem-
bolic risk 
Previous venous thromboembolic event (<3 months)
Atrial fibrillation with a previous embolic event
Mechanical cardiac prosthesis
Thrombophylic disease (congenital or acquired)
Acute myocardial infarction (<3 months)
Ischemic stroke (<1 month)
